Dihexa vs Semax.

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; also referenced as PNB-0408) is a small, orally active peptidomimetic derived from angiotensin IV (Ang IV), a C-terminal fragment of the renin-angiotensin system. It was designed at Washington State University by chemically modifying Ang IV to increase lipophilicity and metabolic stability, yielding a brain-penetrant molecule investigated as a procognitive / antidementia research agent. It is a research chemical, not a drug; it has never been an approved medicine.

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) consisting of the ACTH(4-7) fragment of adrenocorticotropic hormone joined to a C-terminal Pro-Gly-Pro tripeptide. It was developed in the late 1980s/early 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences and is first described in the scientific literature around 1991. The Pro-Gly-Pro extension stabilizes the otherwise rapidly degraded ACTH fragment without retaining ACTH's hormonal (corticosteroid-releasing) activity, making Semax a "neuropeptide" rather than a hormone.

Dihexa was developed from Ang IV, whose procognitive effects were originally studied at the AT4/IRAP site, but its proposed primary mechanism is potentiation of hepatocyte growth factor (HGF) signaling through its receptor tyrosine kinase c-Met, which drives dendritic spine formation (spinogenesis) and synaptogenesis in hippocampal neurons. Activating HGF/c-Met is thought to remodel synaptic connectivity rather than act as a classical neurotransmitter. Important caveat: the central biochemical evidence that dihexa works by binding HGF and augmenting HGF/c-Met activation came from a paper that has since been retracted for data fabrication, so the molecular mechanism should be treated as unproven. The downstream behavioral phenotype (improved spatial learning in rodents) was reported in separate, non-retracted work.

Semax is structurally derived from ACTH(4-10) but lacks the melanocortin-receptor-driven hormonal effects of full-length ACTH, so it does not stimulate cortisol release. Mechanistic (largely rodent and in vitro) work indicates it upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, and modulates expression of NGF and other neurotrophic and immune-response genes, which is proposed to support neuronal survival and synaptic plasticity. A separate biochemical mechanism is inhibition of enkephalin-degrading enzymes in human serum (reported IC50 ~10 µM), which may prolong the activity of endogenous regulatory peptides. The relative contribution of each pathway to any observed clinical effect remains unsettled; Wikipedia and reviews note the precise mechanism of action is not definitively established.

There is NO human data on dihexa: no completed clinical trials, no published human pharmacokinetics or safety. The non-retracted foundational study (McCoy et al., J Pharmacol Exp Ther 2013, PMID 23055539) reported that orally administered dihexa reversed scopolamine-induced learning deficits and improved Morris water maze performance in aged (24-month) rats, and induced spinogenesis in cultured hippocampal neurons at picomolar concentrations. Later angiotensin-IV-analog work continued in disease models (e.g., a 2024 study of an Ang IV analog in a 3-nitropropionic-acid Huntington's-like rat model, PMID 38489193). Crucially, the most-cited mechanistic paper tying dihexa's cognitive effects to HGF/c-Met (Benoist et al., J Pharmacol Exp Ther 2014, PMID 25187433) was RETRACTED in 2025 (retraction notice PMID 40312093) after a Washington State University investigation found falsified/fabricated figure data; the widely repeated "thousands of times more potent than BDNF" claim derives from this now-discredited line of work and should not be cited as established fact. The honest summary: rodent behavioral evidence exists, but the headline mechanistic and potency claims rest partly on retracted literature, and human efficacy is entirely unestablished.

Human evidence comes almost entirely from Russian clinical research and is modest in scale. A representative controlled study by Gusev, Martynov and colleagues (Zh Nevrol Psikhiatr Im S S Korsakova, 2018; PMID 29798983) in 110 ischemic-stroke patients reported that semax plus early rehabilitation raised plasma BDNF and improved motor recovery and functional independence (Barthel index). The strongest mechanistic data, BDNF/TrkB upregulation (Brain Research, 2006; PMID 16996037) and neuroprotection and immune-gene regulation in rat ischemia (Mol Genet Genomics, 2017; PMID 28255762), are preclinical (rat/in vitro). Proposed uses such as ADHD or cognitive enhancement rest largely on hypothesis papers (e.g., Med Hypotheses, 2007; PMID 16996699) rather than rigorous trials. Crucially, no large, independent, randomized, double-blind Western trials have replicated the Russian findings, so the human cognitive- and stroke-benefit claims should be regarded as preliminary.

No human safety data exist; there is no published clinical adverse-event profile, and dihexa is sold only as a research chemical of variable purity. The principal theoretical concern follows directly from its proposed mechanism: c-Met is a validated oncology target because aberrant HGF/c-Met signaling promotes tumor proliferation, invasion, angiogenesis, and metastasis, so a chronic c-Met potentiator raises an unresolved oncogenic-risk question that no human study has addressed. Its reported long circulating half-life and high lipophilicity also mean tissue accumulation and off-target effects are poorly characterized. Because foundational mechanistic data were retracted for fabrication, even the basic biology underlying any risk assessment is uncertain.

Russian clinical reports and the intranasal route describe generally good tolerability, with mild nasal/local irritation the most commonly noted complaint; however, these data come from small studies without the long-term, independent safety surveillance expected for Western drug approval. There is no robust characterization of long-term safety, drug interactions, effects in pregnancy, or risks from non-pharmaceutical "research-use" material sold online, which may vary in purity and sterility. Because much of the mechanistic profile (BDNF/neurotrophin modulation, peptidase inhibition) is extrapolated from animal models, downstream effects of chronic human use are essentially unstudied. Product sold by online vendors is not manufactured to pharmaceutical standards and its identity and contaminants are not guaranteed.

Dihexa is investigational/research-use-only: it is not approved by the FDA or any major regulator for any indication, has no DailyMed monograph, and has not completed human clinical trials. It is not a dietary supplement and is widely sold only as a "research chemical." It is not a WADA-listed named substance, though non-approved experimental compounds are broadly disallowed in sport.

Semax is approved as a prescription drug in Russia (and appears on Russia's List of Vital and Essential Drugs) for indications including ischemic stroke, transient ischemic attack, and cognitive disorders. It is not FDA-approved and is unscheduled in the United States, where it is sold by online vendors as a research/non-pharmaceutical product; it is not approved or marketed in most countries outside Russia.